Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that apply to species and population dynamics as related to adaptation and extinction to populations of cancer cells that similarly adapt and that we are attempting to make extinct, resulting in a cure for the patient. Such principles include an initial intense first strike to deplete the bulk of the cancer cells, followed by a series of sequential second strikes t

Trial Details

NCT ID
NCT07194044
Phase
PHASE1
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Ifosfamide
  • Actinomycin
  • Irinotecan
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Hartford, Connecticut, United States|41.76371,-72.68509
  • Gainesville, Florida, United States|29.65163,-82.32483
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • Patients must be \>1 year of age. There is no upper age limit.
  • Patients, in the opinion of the enrolling investigator, must be healthy enough to tolerate protocol therapy.
  • Patients must have a new histologic diagnosis of either: widely metastatic Ewing sarcoma or metastatic CIC-rearranged sarcoma.
  • Patients must have sufficient tissue submitted (flash frozen tissue, FFPE block, or up to 10 unstained FFPE slides) for correlative testing. This m…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →